Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery

A flurry of preclinical studies builds the case for the integrated stress response as a central driver of many diseases

Less than a month after raising a $525 million series D round led by Softbank, Oxford, U.K.-based AI play Exscientia Ltd. has expanded its collaboration with Bristol Myers Squibb Co. (NYSE:BMY) to

Quentis launches from Glimcher lab with $48M to target ER stress in cancer

Unfolding how cancer cells share ER stress-induced survival signals